Skip to Main Content
Ralf Landgraf, Ph.D.

Ralf Landgraf, Ph.D.

Department:

Biochemistry and Molecular Biology

Ralf Landgraf, Ph.D.
Message Send!
Send a Message

Roles

  • Associate Professor of Biochemistry and Molecular Biology
  • Member Sylvester Comprehensive Cancer Center
  • Director, Cancer Biology Graduate Program
  • Primary Appointment: Biochemistry and Molecular Biology
  • Director, Cancer Biology Graduate Program
  • Biography

    Dr. Landgraf earned his master's in Biochemistry in 1990 at the University of Tuebingen, Germany with additional research time in Enzymology at Queen Mary College, London. He received his PhD in Physiological Chemistry in 1995 at UCLA working on molecular recognition in Protein-DNA interactions, and he did a postdoc in structural studies and computational protein work with David Eisenberg. He started as faculty in Hematology-Oncology at UCLA in 2001 working on ERBB2/3 signaling in breast cancer and joined the Department of Biochemistry and SCCC at UM in 2008. Dr. Landgraf has served as director of the Cancer Biology Graduate program since 2016.
  • Education & Training

    Education

    • 1995
      University of California, Los Angeles, CA
      PhD, Biological Chemistry
    • 1990
      Eberhardt Karls Universitaet, Tuebingen, Germany
      MS, Physiological Chemistry (5 year degree plus 1 year Thesis Project)

    Post Graduate Training

    • 2001
      University of California, Los Angeles, CA
      Post-Doctoral Fellowship, Protein Structure Function Analysis, Bioinformatics
    • 1995
      Merck Academic Development Program
      Post-Doctoral Fellowship
  • Honors & Awards

      Loading...

      No result found

    • Teaching Interests

      Biochemistry classes at the Undergraduate and Master's levelCancer Biology classes relevant to signaling and drug development.
    • Research Interests

      Dr. Landgraf’s research focuses on mechanistic and molecular interaction studies in the context of cancer signaling. For many years, this has emphasized signaling by receptor tyrosine kinases, especially ERBB3 and ERBB2. This included the role of various receptor association and activation states with regard to sensitivity or resistance to treatment with Herceptin, receptor maturation processes, and the role of the immediate membrane context in signal modulation. This work also pioneered the development and use of aptamers as functional probes. In recent years, the focus has shifted towards GPCR signaling in DLBCL, specifically roles of SMO that contribute to drug resistance and that are not part of the established modes of receptor function, as well as the bidirectional regulation of signaling relevant membrane components. This work continues to be mechanistic in nature.
    • Publications

      Loading...

      No result found

        Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
      • Professional Activities

          Loading...

          No result found